Auris Health engages in the development of robotics technology for medical applications, in particular endoscopy, which is a procedure that lets doctors diagnose or deliver treatment to a patient's organs through their natural bodily openings without incision. According to the company, its Monarch Platform improves upon existing minimally invasive techniques by integrating robotics, micro-instrumentation, endoscope design, sensing, and data science into one platform to enable new categories of care. Auris states that every element of its technology is driven by patient-centric design aimed at maintaining the integrity of the human body. Lung cancer is the first disease targeted by Auris, which states that more patients die every year from lung cancer than from prostate, breast and colon cancer combined. The company claims that lung cancer is deadly because it is usually diagnosed late and treatment can be ineffective. To that end, Auris designed the Monarch Platform to allow physicians to accurately access small and hard-to-reach lung nodules early, for diagnosing and targeting treatment. Auris had been in "stealth" for nearly a decade, but in March 2018, it attained FDA approval for its Monarch Platform to be used for "bronchoscopic procedures," such as diagnosing lung cancer.
The company was incorporated in 2007 and is based in the San Francisco Bay area.
*Based on Preferred Stock Price, Auris Health, Inc. does not have a stock symbol since it is currently private and is yet to have an IPO.
Some data provided by Crunchbase
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Auris Health, Inc. or any companies featured above.
This profile is based on publicly available information and is intended to be informative in nature.
To learn more about whether you're eligible, typical investment size, company valuation, and share price, request access here.